Swedish biopharma company Calliditas Therapeutics AB (STO:CALTX) announced on Thursday that its partner Viatris Pharmaceutical Japan G.K. has initiated a Phase 3 clinical trial of Nefecon (VR-205) in Japanese patients with IgA nephropathy (IgAN).
The bridging study in Japan requires a limited number of Japanese patients and mirrors the design of the global NefIgArd trial.
A type of kidney disease, IgA nephropathy is a serious condition that affects an estimated 33,000 patients in Japan, with limited treatment options.
LEO Pharma reports positive phase 2b results for temtokibart in atopic dermatitis
New England Biolabs achieves B Corporation recertification
Palatin presents symptom resolution data from Phase 3 dry eye disease trial
BioArctic expands exidavnemab trial to include Multiple System Atrophy patients
NeuroSense Therapeutics completes PrimeC commercial manufacturing scale-up
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial